Osamu Shiraishi

Osamu Shiraishi

Auto-generated profile, based on publicly available information

Osamu Shiraishi

Department of Surgery, Kindai University Faculty of Medicine , Osaka-sayama

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016 in Oncology
Verified
Journal Article
Closed access
PDF file
OSOsamu Shiraishi
Osamu Shiraishi
MYMakoto Yamasaki
Makoto Yamasaki
TMTomoki Makino
Tomoki Makino
MMMasaaki Motoori
Masaaki Motoori
HMHiroshi Miyata
Hiroshi Miyata
TYTakushi Yasuda
Takushi Yasuda
Background: Neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma (ESCC) requires reassessment. We have conducted a trial aiming at the comparison between DCF and ACF concerning perioperative adverse events. Methods: Patients were randomly assigned to receive either DCF [docetaxel 70 mg/m2, cisplatin 70 mg/m2 on day 1, and 5-fluorouracil (5-FU) 700 mg/m2 for 5 days] every 3 weeks or ACF (adriamycin 35 mg/m2, cisplatin 70 mg/m2 on day 1, and 5-FU 700 mg/m2 for 7 days) every 4 weeks. Each group consisted of 81 patients. Two cycles of preoperative chemotherapy were planned, after which patients underwent subtotal esophagectomy via a right thoracotomy with lymphadenectomy. Chemotherapy- and surgery-related adverse effects were assessed. Results: Grade 3-4 neutropenia and febrile neutropenia occurred in 90 and 39% of patients, respectively, in the DCF group compared with 69 and 17% of patients, respectively, in the ACF group (p < 0.01). Perioperative complications did not differ significantly between the groups. The overall response rates of DCF and ACF were 61 and 40%, respectively, while the histopathological complete responses were 15 and 3%, respectively (p < 0.01). Conclusion: The DCF and ACF regimens were found to be equally feasible in patients with resectable advanced ESCC; however, DCF delivered an antitumor effect and therefore potentially improved the long-term outcomes.

14 May 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
OSOsamu Shiraishi
Osamu Shiraishi
TYTakushi Yasuda
Takushi Yasuda
HKHiroaki Kato
Hiroaki Kato
MIMitsuru Iwama
Mitsuru Iwama
YHYoko Hiraki
Yoko Hiraki
MIMotohiro Imano
Motohiro Imano

25 March 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
OSOsamu Shiraishi
Osamu Shiraishi
TYTakushi Yasuda
Takushi Yasuda
HKHiroaki Kato
Hiroaki Kato
KMKota Momose
Kota Momose
YHYoko Hiraki
Yoko Hiraki
MIMotohiro Imano
Motohiro Imano

9 February 2022 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
OSOsamu Shiraishi
Osamu Shiraishi
TYTakushi Yasuda
Takushi Yasuda
HKHiroaki Kato
Hiroaki Kato
KMKota Momose
Kota Momose
YHYoko Hiraki
Yoko Hiraki
MIMotohiro Imano
Motohiro Imano

9 December 2019 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
OSOsamu Shiraishi
Osamu Shiraishi
HKHiroaki Kato
Hiroaki Kato
MIMitsuru Iwama
Mitsuru Iwama
YHYoko Hiraki
Yoko Hiraki
AYAtsushi Yasuda
Atsushi Yasuda
TYTakushi Yasuda
Takushi Yasuda

25 April 2024 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
THTakaomi Hagi
Takaomi Hagi
OSOsamu Shiraishi
Osamu Shiraishi
TNTomoya Nakanishi
Tomoya Nakanishi
MKMasashi Kohda
Masashi Kohda
YHYoko Hiraki
Yoko Hiraki
TYTakushi Yasuda
Takushi Yasuda